Myrexis, Inc. announced that its board of directors has appointed Richard B. Brewer as President and Chief Executive Officer, and David W. Gryska as Chief Operating Officer, effective from May 11, 2012. In addition, both Mr. Brewer and Mr. Gryska have been appointed to Myrexis' board of directors. Mr. Brewer is the former Chief Executive Officer of Scios, Inc. and has served as Chairman of several biotechnology companies. Mr. Gryska is the former Senior Vice President and Chief Financial Officer of Celgene Corporation. Mr. Brewer and Mr. Gryska will work closely with the board and Myrexis' financial advisor Stifel Nicolaus Weisel to implement the Company's new strategy. In connection with these management changes, Robert J. Lollini has stepped down as President and Chief Executive Officer and will continue on Myrexis' board for a transition period through November 15, 2012. Andrea Kendell will remain Chief Financial Officer of Myrexis.
Myrexi, Inc. is a development-stage company. The Company was a biopharmaceutical company that generated a pipeline of differentiated drug candidates in oncology and autoimmune diseases. In February 2012, it announced that the Company has suspended development activity on all of its preclinical and clinical programs and retained Stifel Nicolaus Weisel, an investment banking firm, to assist in reviewing and evaluating a full range of strategic alternatives to enhance shareholder value. The Company determines to pursue the acquisition of one or more commercial-stage biopharmaceutical assets, with the goal of building a commercial-stage biopharmaceutical company. The Company operates in pharmaceutical development and related research activities. The Companyâs revenues were derived from research performed in the United States and, all of the Companyâs long-lived assets are located in the United States.
MYREXIS, INC. 
